Exhibit 99.1 Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results Selective Kv7 Ion Channel Activator (Opakalim): NEW HAVEN, Conn., May 4, 2026 /PRNewswire/ – Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life- changing therapies to treat a broad range of rare and common diseases, today reported financial results for the first quarter ended March 31, 2026 ...